Nanobodies Market Growth By Global Players Novo Nordisk A/S, Merck & Co., Inc., Merck KGaA

1. Nanobodies Market Growth By Global Players Novo Nanobodies Market Growth By Global Players Novo Nordisk A/S, Merck & Co., Inc., Merck KGaA Nordisk A/S, Merck & Co., Inc., Merck KGaA Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and therapy especially in cancer research. These technology was developed from antigen binding fragments, originating from Camelid heavy-chain antibodies. These molecules do not have light chains, which is an essential part of antibodNanobodies Market Growth By Global Players Novo Nordisk A/S, Merck & Co., Inc., Merck KGaAy found in humans. Based on the above finding, nanobodies molecule containing single-domain only were developed, and these molecules contain functional and structural properties similar to heavy chain antibodies. These molecules have several advantages as compared to the conventional antibodies such as small-size, nano to picomolar affinities, and multiple route of administration. Ablynx, which is acquired by Sanofi S.A., is one of the leading company in this market. Get Sample Copy At: Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1680 https://www.coherentmarketinsights.com/insight/request-sample/1680 Nanobodies Market Drivers Nanobodies Market Drivers Currently, no products are available in the market, but there are multiple products in the pipeline including few in very late stage of clinical trials. For instance, marketing authorization application for Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) has been submitted to European Medicine Agency (EMA) in February 2017. The product, Caplacizumab, is expected to be launched in Europe in 2018. Moreover, the company, Ablynx, is expected to file for biologic license agreement to the U.S. Food and Drug Administration (FDA) in 2018, and is expected to launch this product in U.S. in 2019. Both, Europe and U.S. are the key markets for any biologics including monoclonal antibodies and are expected to be the high revenue generating market for nanobodies. Hence, approval by regulatory bodies in Europe and U.S. to Caplacizumab in very near future (i.e. 2018, 2019) is expected to drive the growth of global nanobodies market. As per the company, Ablynx, estimates the product has potential to generate more than US$ 1 Bn. Furthermore, there are multiple products in early stage of clinical development i.e. preclinical, phase 0, and phase 1. Ablynx alone had 8 products in clinical development phase (i.e. phase 0 to phase 3) and overall 45 products in pipeline as of March 2017.

2. Lucrative potential in the market has motivated leading biotechnology companies such as C.H. Boehringer Sohn AG & Ko. KG, MERCK KGaA, Merck & Co., Inc., AbbVie, Inc., Novo Nordisk A/S and Sanofi S.A. to collaborate or enter into a partnership agreement with the nanobodies manufacturer, Ablynx. In July 2017, Ablynx entered into a research collaboration and licensing agreement with Sanofi S.A. for the treatment of various immune-mediated inflammatory diseases. As per the agreement, Sanofi S.A. will get access to Ablynx’s scientists and technology platforms, and also, to certain drugs in pipeline. Furthermore, in 2015, Ablynx and Merck & Co., Inc. expanded their collaboration agreement focused on immuno-oncology. In January 2018, Sanofi S.A. made an offer to acquire Ablynx, and the offer was unanimously recommended by Ablynx board. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Nanobodies Market Research Objective and Assumption • Nanobodies Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Nanobodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Nanobodies Market, By Regions • Nanobodies Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Nanobodies Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Nanobodies Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Nanobodies Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Nanobodies Market Regional Analysis Nanobodies Market Regional Analysis

3. Europe is expected to hold dominant position in global nanobodies market, owing to the first mover advantage. Marketing authorization application (MMA) to EMA for Caplacizumab was filed by Ablynx in February 2017, and the company expects to get approval in 2018. If approved, Europe will be the only market to have nanobodies commercially available. However, North America is expected to show rapid growth in this market, as the company is planning to file for biologic license agreement for the same product to U.S. FDA in 2018, and expects to get approval from FDA by 2019. Once approved in U.S., the company may plan to reap the maximum benefit out of it. Furthermore, the drug, Caplacizumab, is expected to have better efficiency compared to both the available treatment (i.e. plasma exchange therapy and immunosuppressant) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In Asia Pacific, Japan may take the lead as multiple products such as Caplacizumab, Vobarilizumab, and ALX- 0171 has successfully gone through initial phase of clinical development. Nanobodies Market Restraint Nanobodies Market Restraint Presently, there are no products in market, and more than two-third products in very early phase of development, and these products have to go through various phases of clinical development. Failure in clinical trials for these products or slow approval by the regulatory bodies in the market may prove to be vital restraint in this market. Browse Complete Report For More Information @ Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/nanobodies-market-1680 https://www.coherentmarketinsights.com/ongoing-insight/nanobodies-market-1680 Nanobodies Market Key Players Nanobodies Market Key Players Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover, the company is developing various products with leading biology companies such as Novo Nordisk A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn AG & Ko. KG. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah

4. Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702